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Lung cancerAbstract Idiopathic pulmonary ﬁbrosis (IPF) is a speciﬁc form of chronic, progressive ﬁbrosing
interstitial pneumonia of unknown cause, occurring primarily in older adults and limited to the
lungs. IPF is a disease with similarities and links to cancer biology whose main event is aberrant
cell proliferation. Although toll like receptors (TLRs) are essential for protective immunity, inap-
propriate TLR responses contribute to inﬂammation. Chronic inﬂammation is one of the risk fac-
tors and features of cancer. It can affect any stage of tumorigenesis and migration of cancer cell.
Aim of work: To investigate the key role of TLR4 expression in the development and progression
of lung cancer and IPF and its contribution as a common pathway in the development of both.
Methods: This study included 16 IPF patients, 20 lung cancer patients and 23 control subjects.
All patients were subjected to full history taking, detailed clinical examination, radiological assess-
ment, bronchoscopic biopsies and serum samples for measurement of TLR4 expression. TLR4 was
measured in serum of all control subjects and in bronchoscopic biopsies for only ﬁve of them.
Results: TLR4 expression was higher in serum and tissue biopsies of IPF and lung cancer patients
than that in the control group; however the highest level of LTR4 expression in serum was observed
in the IPF group and the highest level in tissue biopsy was observed in the lung cancer group. TLR4 levels
were not signiﬁcantly different between the three studied groups. There was a signiﬁcant association
between TLR4 expression in tissue biopsy and distant metastasis among NSCLC cases (p= 0.006).
Conclusion: Our results support that TLR4 pathway may be a common contribution to both diseases.
There was association between distant metastasis and TLR4 expression. Further studies are needed to
evaluate the TLR4 prognostic value for tumor progression and its expression in precancerous lesions.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
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Idiopathic pulmonary ﬁbrosis is a speciﬁc form of chronic,
progressive ﬁbrosing interstitial pneumonia of unknown cause,
occurring primarily in older adults and limited to the lungs [1].
IPF is a disease with similarities and links to cancer biology. A
number of pathogenetic hypotheses are shared by both fatal
diseases, whose main event is aberrant cell proliferation [2].
Human TLRs are a family of trans-membrane receptors that
consist of ten members and play a key role in innate immune
defense, particularly in inﬂammatory response against various
invading exogenous pathogens [3,4].
Although TLRs are essential for protective immunity
against infection, inappropriate TLR responses contribute to
acute and chronic inﬂammation, as well as to systemic autoim-
mune diseases [5,6]. Activation of TLR signaling in the steady state
maintains tissue architecture. However, in the presence of deregu-
lated inﬂammation and/or tissue injury, as occurs in ﬁbrogenesis
and tumorigenesis, the TLR-driven tissue response may promote
tissue remodeling, neoangiogenesis and tumor growth by mecha-
nisms that are still poorly deﬁned [7].
TLRs are expressed in a variety of cells, including type II
alveolar epithelial cells, airway epithelial, smooth muscle cells,
and ﬁbroblasts [8]. TLR4 is a key regulator of the pro-
inﬂammatory transcription factor nuclear factor kappa B
(NF-jB) and plays a dominant role in mediating sterile tissue
damage. IjB kinase (IKK) activation leads to the dissociation
of NF-jB from IjB and its subsequent activation [9].
The mechanism of TLR4 activation involves several auxil-
iary proteins as well as a co-receptor ‘‘myeloid differentiation
factor 2” (MD-2) [10]. MD-2 is a soluble protein that repre-
sents the binding site for the acyl chains of lipid A. Lipid A
is usually composed of 6 acyl chains, but only 5 of them bind
to MD-2. The 6th acyl chain interacts with residues on TLR4.
This MD-2/TLR4 heterodimerization is a prerequisite for the
activation of the TLR4 signaling cascade [11,12]. The
endotoxin/MD-2/TLR4 heterodimer can trigger the transcrip-
tion of both proinﬂammatory cytokines as well as type I inter-
ferons [10].
It is therefore not too surprising that TLR4 activation
affects not only the immune response against invading
Gram-negative bacteria but is also involved in chronic inﬂam-
mation, autoimmune diseases and malignancies. TLR4 signal-
ing in cancer is considered a double-edged sword. If TLR4 is
activated on immune cells, it can enhance anti-tumor immu-
nity. On the other hand, chronic inﬂammation is a major risk
factor in cancer development [13].
Chronic inﬂammation has emerged as one of the main risk
factors and features of cancer. It can affect any stage of
tumorigenesis, generating a microenvironment conducive to
tumor development and progression, and promoting the sur-
vival, proliferation and migration of cancer cells. Thus, many
cancers can arise from local irritation, inﬂammation and
chronic infection. Changes in proteins or receptors involved
in the inﬂammatory and immune responses may contribute
to an increased risk of developing cancer. TLRs activate the
NF-jB pathway, the main regulatory inﬂammation signaling
pathway, and this activation is involved in the pathogenesis
of cancer [14].
Emerging evidence suggests that chemoresistance is pro-
moted by substances released from dead and damaged cellsthat activate the host repair program orchestrated by TLR4.
TLR4 is often over-expressed in malignant and tumor inﬁltrat-
ing immune cells. TLR4 activation promotes local and sys-
temic inﬂammation, leading to the induction of multiple
circuits that create a regenerative environment favoring local
recurrence and metastasis. Of particular importance is
TLR4-mediated recruitment of endothelial progenitors derived
from immature myeloid cells. These cells play a major role in
rebuilding tumor-associated lymphatic and blood vessels,
thereby promoting lymphatic and hematogenous metastasis
[15].
The aim of the present study was to investigate the key role
of TLR4 expression in the development and progression of
lung cancer and IPF and to study TLR4 contribution as a
common pathway in the development of both.
Patients and methods
The present study included 59 subjects who were sub-grouped
into; sixteen patients with the diagnosis of IPF, twenty patients
with bronchogenic carcinoma and twenty-three control sub-
jects. All patients were recruited from chest departments,
Cairo University and Fayoum University Hospitals in the per-
iod from January 2014 to June 2015. Informed consent was
obtained from all patients who participated in the study. The
study was approved by the research ethics committee, Faculty
of Medicine, Cairo and Fayoum Universities.
IPF: They were diagnosed based on the guidelines of the
international consensus statement produced as a collaborative
effort from the ATS, ERS, JRS and ALAT [1]. All IPF
patients were newly diagnosed and had not received any treat-
ment and patients with any known cause of pulmonary ﬁbro-
sis, such as a systemic connective tissue disorder, were
excluded by both immunologic screening and rheumatological
clinical evaluation. All IPF patients were subjected to full his-
tory taking including smoking and occupational history,
detailed clinical examination, arterial blood gases analysis,
spirometry, 6-min walk test, echocardiography with assess-
ment of the pulmonary artery systolic pressure and high-
resolution computed tomography of the chest. For evaluation
of interstitial involvement with HRCT, ﬁbrosis score or inter-
stitial score as described by Gay et al. in (1998) [16] was used.
In this method each lobe of the lung was separately scored for
the presence, distribution and extent of honeycombing and
interlobular septal thickening on a scale of 0–5 as follows:
(0) no interstitial disease, (1) septal thickening without honey-
combing, (2) honeycombing involving up to 25% of the lobe,
(3) honeycombing involving 25–49% of the lobe, (4) honey-
combing involving 50–75% of the lobe, (5) honeycombing
involving >75% of the lobe. Honeycomb cysts were deﬁned
as localized areas of decreased attenuation with well deﬁned
walls. The lingula was scored as a separate lobe. After each
lobe was scored individually, an average score for all lobes
was obtained and used for the statistical analysis.
Bronchogenic carcinoma: All patients were subjected to full
history taking including smoking history. Patients underwent
radiological assessment to detect primary tumor site, pleural
or mediastinal lymph nodes involvement and distant metasta-
sis. The patients included in the study were diagnosed based on
histopathological criteria from endobronchial biopsies and
they had not received any treatment for lung cancer. The
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diagnosis into small cell lung cancer (SCLC) and non small cell
lung cancer (NSCLC). Patients with NSCLC were subdivided
into adenocarcinoma, squamous cell carcinoma and large cell
carcinoma according to WHO classiﬁcation in 1999 [17].
Control group: included 23 subjects; 5 were patients who
underwent bronchoscopy for the investigation of hemoptysis,
without any pulmonary comorbidities and with normal bron-
choscopic ﬁndings while the remaining 18 subjects were
healthy control.
Methods
 Bronchoscopic biopsies for TLR4 detection: TBLBs were
obtained from the basal segments of the right lower lobe
of IPF patients, while endobronchial biopsies from endo-
bronchial tissue growth were performed for patients with
bronchogenic carcinoma. Also bronchial mucosal biopsies
were done for only the symptomatic control subjects (5
patients). For all patients biopsies were divided into 2 parts,
one was immersed immediately in a bottle containing 10%
formalin solution and sent for histopathological assessment
while the other was put in 1 ml Phosphate Buffer Saline
(PBS) for further lab processing and TLR4 determination.
 Tissue biopsy sample processing for protein extraction: Tis-
sue biopsy punches were rinsed with 1X PBS, homogenized
in 1 ml of 1X PBS and stored overnight at 20 C. After
two freeze–thaw cycles were performed to break the cell
membranes, the homogenates were centrifuged for 10 min
at 5000g. The supernatant was stored at 80 C until anal-
ysis. Total protein concentrations in the supernatant were
determined using a protein in ﬂuids assay kit (pyrogallol
red/molybdate principle) (Dialab GmbH, Wiener Neudorf,Table 1 Characteristics of study groups.
Study groups
Lung
cancer
(n= 20)
IPF
(n= 16)
Control
group
(n= 23)
Male:Female (n) 16:4 10:6 15:8
Age
(median) (years) 57 43 43
Range 35–77 20–70 20–70
Current smokers (No., %) 12 (60%) 3 (18.8%) 8 (34.8%)
Table 2 Statistical comparison between study groups according to
Study groups
Lung cancer
TLR4 in the serum (ng/ml)
Number 20
Median (25th–75th percentile) 3.99 (0.94–19.58)
TLR4 in tissue (ng/mg protein)
Number 20
Median (25th–75th percentile) 0.94 (0.33–2.56)Austria) and were used for normalization of tissue TLR4
levels where TLR4 in lung tissue was expressed as ng/mg
protein.
 Serum Sample for TLR4 level estimation: Blood samples
were withdrawn from all study groups. Samples were cen-
trifuged, serum was separated and immediately stored at
80 C until analysis
 Determination of TLR4 levels in serum and tissue:Was done
using a commercially available enzyme-linked immunosor-
bent assay (ELISA) kit for quantitative determination of
human toll like receptor 4 (TLR4) (Cusabio Biotech Co.,
Ltd., China), according to the manufacturer’s instructions.
 Statistical analysis of the results: Data were statistically
described in terms of mean ± SD, median and range, or
frequencies (number of cases) and percentages when appro-
priate. Comparison of numerical variables between the
study groups was done using the Mann Whitney U test
for independent samples when comparing 2 groups and
Kruskal–Wallis test with post hoc multiple 2-group com-
parisons when comparing more than 2 groups. For compar-
ing categorical data, Chi square (v2) test was performed.
Exact test was used instead when the expected frequency
is less than 5. Correlation between various variables was
done using Pearson moment correlation equation for linear
relation in normally distributed variables and Spearman
rank correlation equation for non-normal variables/non-
linear monotonic relation. p values less than 0.05 was con-
sidered statistically signiﬁcant. All statistical calculations
were done using computer program SPSS (Statistical Pack-
age for the Social Science; SPSS Inc., Chicago, IL, USA)
release 15 for Microsoft Windows (2006).
Results
The study included 59 subjects who were sub-grouped into;
sixteen patients with the diagnosis of IPF, twenty patients with
bronchogenic carcinoma and twenty-three control subjects.
The lung cancer patients (16 males and 4 females) had a med-
ian age of 57 years; IPF patients (10 males and 6 females) had
a median age of 43 years and the control group (15 males and 8
females) had a median age of 43 years. Regarding smoking
prevalence among the study groups, the numbers of current
smokers were twelve patients in the lung cancer group, three
patients in the IPF group and eight subjects in the control
group (Table 1).
Table 2 presents the value of TLR4 in serum and tissue
among the three studied groups. TLR4 expression was higherthe value of TLR4 in serum and tissue biopsies.
IPF Control group p value
16 23
12.46 (0.85–16.10) 1.07 (0.84–6.03) 0.682
16 5
0.53 (0.29–4.05) 0.17 (0.14–0.79) 0.515
Table 3 Characteristics of the lung cancer group.
Lung cancer group (n= 20)
Histopathological subtypes (No. %)
SCLC
NSCLC 3 (15.0%)
NSCLC subtypes: 17 (85.0%)
Adenocarcinoma 9 (45.0%)
Large cell carcinoma 2 (10.0%)
Squamous cell carcinoma 6 (30.0%)
Pleural involvement (No., %) 3 (15.0%)
Mediastinal L.N involvement (No., %) 9 (45.0%)
Distant metastasis (No., %) 5 (25.0%)
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than in the control group; however the highest level of LTR4
expression in the serum was observed in the IPF group
(Fig. 1) and the highest level in tissue biopsy was observed in
the lung cancer group (Fig. 2). TLR4 levels were not signiﬁ-
cantly different between the three studied groups.
During histopathological evaluation of the lung cancer
group, SCLC was found in 15% (3 patients) while NSCLC
(85%) was found in 85% (17 patients). NSCLC included sev-
eral subtypes: adenocarcinoma (45%), large cell carcinoma
(10%) and squamous cell carcinoma (30%). Among the lung
cancer group; pleural involvement was present in 15%, medi-
astinal lymph node (L.N) involvement in 45% and distant
metastasis in 25% as shown in Table 3.
In the lung cancer group (Table 4): it was observed that the
TLR4 level was higher in the serum of patients who were cur-
rent smokers and had pleural effusion, mediastinal L.N
involvement and distant metastasis without statistical signiﬁ-
cance. On the other hand the TLR4 level in tissue biopsiesGroup
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Figure 1 Comparison between the study groups according to
TLR4 levels in serum samples.
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Figure 2 Comparison between the study groups according to
TLR4 levels in tissue biopsies.was higher in patients with mediastinal L.N involvement and
distant metastasis with statistical signiﬁcance regarding distant
metastasis (p= 0.006) (Figs. 3 and 4).
In the IPF group: TLR4 in the serum showed a negative
correlation with PASP, PaCO2 and HRCT score while it
showed a positive correlation with PaO2, SaO2%, FVC%,
FEV1%, FEF25–75% and 6MWD. Regarding TLR4 in tissue,
there was negative correlation with PaO2, SaO2%, FVC%,
FEV1%, FEF25–75% and 6MWD and a positive correlation
with PASP, PaCO2 and HRCT score. All correlations were
insigniﬁcant as shown in Table 5.
Discussion
Recent observations support the hypothesis that IPF may not
be just an inﬂammatory disorder but rather a complex process
characterized by abnormal pneumocyte apoptosis and pro-
found derangement of alveolar renewal, making it, at least in
some aspects, more similar to malignant lung disease. TLR-
driven inﬂammation seems to play a role in furthering
malignant development in a wide context of ways [2]. TLR4
activation alters the balance of progrowth and antigrowth
cytokines in the extracellular microenvironment, ultimately
resulting in increased proliferation and growth [18].
TLRs are considered to be expressed in both immune cells
and tumor cells. For this the present study aimed to investigate
the key role of TLR4 expression in the development and pro-
gression of lung cancer and IPF and to study TLR4 contribu-
tion as a common pathway in the development of both.
In the present study, it was observed that TLR4 expression
was higher in serum and tissue biopsies of IPF and lung cancer
patients than in the control group; however the highest level of
LTR4 expression in serum was observed in the IPF group and
the highest level in tissue biopsies was observed in the lung
cancer group. TLR4 levels were not signiﬁcantly different
between the three studied groups.
IPF is characterized by excessive scarring of the lung par-
enchyma. Despite considerable progress in deﬁning the natural
history of the disease, many features of IPF pathogenesis
remain poorly understood. Several recent studies have high-
lighted links between pattern recognition receptors of innate
immunity termed ‘‘Toll-like receptors” and the aberrant ﬁbro-
genesis that characterizes IPF [19].
There was a study done by Samara et al. in 2012 [20] on
expression proﬁles of toll like receptors in non-small cell lung
cancer and idiopathic pulmonary ﬁbrosis. TLR expression was
Table 4 Relationship between serum and tissue biopsy levels of TLR4 and characteristics of the lung cancer group.
Character Lung cancer
(n= 20)
Serum TLR4*
(ng/ml)
p value Tissue TLR4*
(ng/mg protein)
p value
Smoking history Absent 8 (40%) 2.38 (0.81–12.98) 0.44 1.32 (0.35–3.51) 0.758
Present 12 (60%) 9.78 (0.99–20.09) 0.85 (0.33–2.28)
Pleural eﬀusion Absent 17 (85%) 1.48 (0.88–19.55) 0.186 1.04 (0.34–2.54) 0.634
Present 3 (15%) 15.73 (3.29–34.18) 0.44 (0.17–3.84)
Mediastinal L.N involvement Absent 11 (55%) 1.48 (0.99–19.50) 0.569 0.84 (0.32–1.39) 0.732
Present 9 (45%) 4.70 (1.08–20.29) 1.81 (0.28–3.21)
Distant metastasis Absent 15 (75%) 1.47 (0.99–17.85) 0.275 0.45 (0.31–1.39) 0.006**
Present 5 (25%) 19.61 (1.24–20.61) 4.67 (1.81–6.07)
* Data are presented as median (25th–75th percentiles).
** p value < 0.05 equal statistically signiﬁcant.
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Figure 3 Relationship between serum TLR4 levels and distant
metastasis.
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Figure 4 Relationship between tissue TLR4 levels and distant
metastasis.
Table 5 Correlation of TLR 4 in serum and tissue with the
characteristics of the IPF group.
TLR4 in the serum TLR4 in the tissue
r p r p
PASP mm Hg 0.231 0.494 0.438 0.178
PaO2 mm Hg 0.276 0.300 0.301 0.257
PaCO2 mm Hg 0.276 0.301 0.186 0.489
SaO2% 0.318 0.230 0.232 0.387
HRCT score 0.119 0.660 0.142 0.599
FVC% 0.346 0.190 0.094 0.728
FEV1% 0.304 0.253 0.028 0.917
FEF25–75% 0.158 0.559 0.286 0.284
6MWD (m) 0.167 0.536 0.409 0.116
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polymerase chain reaction (RT-PCR) in bronchoalveolar
lavage ﬂuid of 16 IPF patients, 16 non-small cell lung cancerpatients and 9 control subjects. They found that TLR4 expres-
sion was similar in both diseases and the control group as well.
In 2007, He et al. [21] described the expression of TLR4 in
human lung cancer cells. Oblak and Jerala in 2011 [22] found
that TLR4 is expressed on a variety of immune as well as
tumor cells, but its activation can have opposing effects. While
TLR4 activation can promote antitumor immunity, it can also
result in increased tumor growth and immunosuppression.
TLR4 mediated signaling has been implicated in tumor cell
invasion, survival and metastasis in several types of cancers
[23]. Remarkably, the present study showed that the TLR4
level was higher in the serum of lung cancer patients (NSCLC
cases) who had pleural effusion, mediastinal L.N involvement
and distant metastasis without statistical signiﬁcance. On the
other hand the TLR4 level in the tissue biopsies was higher
in patients with mediastinal L.N involvement and distant
metastasis with statistical signiﬁcance regarding distant
metastasis.
Our ﬁndings agreed with Liu et al. in 2015 [24] who demon-
strated a crucial role for TLR4 signaling to enhance the tumor
progression and distant metastasis of NSCLC, which could
further enhance the understanding of NSCLC pathogenesis
and be helpful for developing novel therapeutics for NSCLC.
Also Boi and Elsawa in 2013 [25] mentioned that Nickel has
been shown to be an agonist for TLR4, and Nickle could also
contribute to the progression of human lung cancer by increas-
ing the metastatic potential of the tumor cells by elevating
levels of IL-8, TGF-b, MMP2, and MMP9. Moreover, the
294 S. Ahmed et al.down regulation of TLR4 could signiﬁcantly inhibit the inva-
sive potential of the cells when exposed to nickel.
Within the lung cancer group, it was found that 3 patients
had pleural involvement (15%), 9 patients had mediastinal
lymph node affection (45%) and 5 (25%) patients had distant
metastasis (all of them were NSCLC cases). Tumor progres-
sion to pleura was in a fewer number of patients than the nodal
spread or the distant metastasis.
Apoptosis is one of the main types of programed cell death,
TLR4 modulates cell apoptosis by activating members of
mitogen-activated protein kinase (MAPK) signaling pathways
and leads to the activation of mitochondria-associated apop-
totic cascades [26]. Modulating the proliferation of lung cancer
cells and inhibiting apoptosis is poorly understood, TLR4
could coordinately improve the proliferation of tumor cells
in vitro [27].
The pleural mesothelial cells (PMCs) have many defense
mechanisms including the sialomucin complex on PMCs which
acts as a defense layer. Also PMCs produce signiﬁcant quanti-
ties of hyaluronan and endostatin which induce cell cycle arrest
and apoptosis, inhibit endothelial cell migration, inhibit angio-
genesis and reduce tumor growth [28].
In conclusion, the present study found that TLR4 is over
expressed in serum and tissue of IPF and lung cancer patients
than the control group, so the TLR4 pathway may be a com-
mon contribution to both diseases. There was association
between distant metastasis and TLR4 expression so further
studies are needed to evaluate its prognostic value for tumor
progression. TLR4 expression in precancerous lesions and its
use as a therapeutic target should be tackled in further studies.
Also further studies are needed to highlight the link between
TLR4 and aberrant ﬁbrogenesis that characterize IPF.
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